Successful Laser Treatment of Vandetanib-Associated Cutaneous PigmentationBROOKS, Sara; LINEHAN, W. Marston; SRINIVASAN, Ramaprasad et al.Archives of dermatology (1960). 2011, Vol 147, Num 3, pp 364-365, issn 0003-987X, 2 p.Article

A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor VandetanibGIACCHERO, Damien; RAMACCIOTTI, Constanza; ROBERT, Caroline et al.Archives of dermatology (1960). 2012, Vol 148, Num 12, pp 1418-1420, issn 0003-987X, 3 p.Article

Cutaneous Pigmentation After Photosensitivity Induced by Vandetanib TherapyKONG, Heidi H; FINE, Howard A; STERN, Jere B et al.Archives of dermatology (1960). 2009, Vol 145, Num 8, pp 923-925, issn 0003-987X, 3 p.Article

Methodological aspects of lung cancer clinical trials in the era of targeted agentsDI MAIO, Massimo; GALLO, Ciro; DE MAIO, Ermelinda et al.Lung cancer. 2010, Vol 67, Num 2, pp 127-135, issn 0169-5002, 9 p.Article

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequencesAZZARITI, Amalia; PORCELLI, Letizia; PARADISO, Angelo et al.Cancer chemotherapy and pharmacology. 2010, Vol 65, Num 2, pp 335-346, issn 0344-5704, 12 p.Article

Actualités thérapeutiques: l'abiratérone, le bélatacept, le vandétanib et la fidaxomycine = Four new drugs on the market: Abiraterone, belatacept, vandetanib and fidaxomycineMONNERET, C.Annales pharmaceutiques françaises. 2013, Vol 71, Num 2, pp 95-103, issn 0003-4509, 9 p.Article

Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled studyHSU, Chiun; YANG, Tsai-Sheng; CHENG, Ann-Lii et al.Journal of hepatology. 2012, Vol 56, Num 5, pp 1097-1103, issn 0168-8278, 7 p.Article

Vandetanib for the Treatment of Medullary Thyroid CarcinomaCOOPER, Maryann R; SOO YUN YI; ALGHAMDI, Wael et al.The Annals of pharmacotherapy. 2014, Vol 48, Num 3, pp 387-394, issn 1060-0280, 8 p.Article

Traitements antiangiogéniques au cours des cancers bronchiques = Antiangiogenic treatments in lung cancerSAINTIGNY, P; ETESSAMI, R; MORERE, J. F et al.La Lettre du pneumologue. 2007, Vol 10, Num 5, pp 158-164, issn 1292-5977, 7 p.Article

Vandetanib for the Treatment of Medullary Thyroid CancerCHAU, Nicole G; HADDAD, Robert I.Clinical cancer research (Print). 2013, Vol 19, Num 3, pp 524-529, issn 1078-0432, 6 p.Article

Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse ModelCHOI, Sungweon; SANO, Daisuke; CHEUNG, Melvina et al.Clinical cancer research (Print). 2008, Vol 14, Num 16, pp 5081-5089, issn 1078-0432, 9 p.Article

Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinomaKLEIN, Jonah D; CHRISTOPOULOS, Apostolos; AHN, Sun M et al.Head & neck. 2012, Vol 34, Num 9, pp 1269-1276, issn 1043-3074, 8 p.Article

Vandetanib for the Treatment of Thyroid CancerLANGMUIR, P. B; YVER, A.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 1, pp 71-80, issn 0009-9236, 10 p.Article

Angiogenèse et cancer de la thyroïde : Antiangiogéniques (2e partie) = Angiogenesis and thyroid cancerCOLICHI, C; BILLARD, D; FAIVRE, S et al.La Lettre du cancérologue (Boulogne). 2010, Vol 19, Num 10, pp 596-599, issn 1165-113X, 4 p.Article

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequencesAZZARITI, Amalia; PORCELLI, Letizia; PARADISO, Angelo et al.Cancer chemotherapy and pharmacology. 2010, Vol 65, Num 5, pp 335-346, issn 0344-5704, 12 p.Article

Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy SubjectsMARTIN, Paul; OLIVER, Stuart; KENNEDY, Sarah-Jane et al.Clinical therapeutics. 2012, Vol 34, Num 1, pp 221-237, issn 0149-2918, 17 p.Article

Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumors: An Open-Label, Phase I, Rising Multiple-Dose StudyLI ZHANG; SU LI; YANG ZHANG et al.Clinical therapeutics. 2011, Vol 33, Num 3, pp 315-327, issn 0149-2918, 13 p.Article

The Role of Antiangiogenetic Agents in the Treatment of Breast CancerBARESCHINO, M. A; SCHETTINO, C; COLANTUONI, G et al.Current medicinal chemistry. 2011, Vol 18, Num 33, pp 5022-5032, issn 0929-8673, 11 p.Article

Impact of Tumor Cell VEGF Expression on the In Vivo Efficacy of Vandetanib (ZACTIMA™; ZD6474)SIEMANN, Dietmar W; NORRIS, Christina M; RYAN, Anderson et al.Anticancer research. 2009, Vol 29, Num 6, pp 1987-1992, issn 0250-7005, 6 p.Article

Vandetanib Improves Anti-Tumor Effects of L19mTNFα in Xenograft Models of Esophageal CancerCRESCENZI, Marika; PERSANO, Luca; ESPOSITO, Giovanni et al.Clinical cancer research (Print). 2011, Vol 17, Num 3, pp 447-458, issn 1078-0432, 12 p.Article

Radiosynthesis of [¹¹C]Vandetanib and [¹¹C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancerMINGZHANG GAO; LOLA, Christian M; MIN WANG et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 11, pp 3222-3226, issn 0960-894X, 5 p.Article

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic ImpairmentWEIL, Angelika; MARTIN, Paul; SMITH, Robert et al.Clinical pharmacokinetics. 2010, Vol 49, Num 9, pp 607-618, issn 0312-5963, 12 p.Article

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsMAYER, Erica L; ISAKOFF, Steven J; KLEMENT, Giannoula et al.Breast cancer research and treatment. 2012, Vol 136, Num 1, pp 169-178, issn 0167-6806, 10 p.Article

Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomasKUMMAR, Shivaani; GUTIERREZ, Martin E; TREPEL, Jane et al.European journal of cancer (1990). 2011, Vol 47, Num 7, pp 997-1005, issn 0959-8049, 9 p.Article

A Novel Therapeutic Combination for Neuroblastoma: The Vascular Endothelial Growth Factor Receptor/Epidermal Growth Factor Receptor/Rearranged During Transfection Inhibitor Vandetanib With 13-cis-Retinoic AcidZAGE, Peter E; LIZHI ZENG; PALLA, Shana et al.Cancer. 2010, Vol 116, Num 10, pp 2465-2475, issn 0008-543X, 11 p.Article